Legend Biotech (LEGN) Expected to Announce Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $310.2050 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

Legend Biotech Trading Up 6.9%

LEGN stock opened at $18.97 on Monday. The firm has a fifty day moving average price of $19.60 and a 200 day moving average price of $26.70. Legend Biotech has a fifty-two week low of $16.24 and a fifty-two week high of $45.30. The firm has a market cap of $3.50 billion, a PE ratio of -29.18 and a beta of 0.07. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.80 and a current ratio of 2.86.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in shares of Legend Biotech by 4.4% in the 4th quarter. Invesco Ltd. now owns 13,710 shares of the company’s stock valued at $298,000 after purchasing an additional 581 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Legend Biotech by 171.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock worth $34,000 after purchasing an additional 662 shares during the last quarter. Fox Run Management L.L.C. grew its stake in shares of Legend Biotech by 4.3% during the fourth quarter. Fox Run Management L.L.C. now owns 20,806 shares of the company’s stock worth $452,000 after purchasing an additional 863 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in shares of Legend Biotech by 31.0% during the third quarter. Public Employees Retirement System of Ohio now owns 3,800 shares of the company’s stock worth $124,000 after purchasing an additional 900 shares in the last quarter. Finally, Royal London Asset Management Ltd. increased its holdings in Legend Biotech by 2.0% in the second quarter. Royal London Asset Management Ltd. now owns 60,800 shares of the company’s stock valued at $2,158,000 after buying an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 70.89% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Jefferies Financial Group set a $21.00 price objective on shares of Legend Biotech in a research report on Thursday, January 22nd. Cantor Fitzgerald reduced their target price on shares of Legend Biotech from $75.00 to $74.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Raymond James Financial reaffirmed an “outperform” rating on shares of Legend Biotech in a report on Monday, February 23rd. Oppenheimer began coverage on Legend Biotech in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $75.00 price target for the company. Finally, Truist Financial cut Legend Biotech from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.08.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.